Analyzing CorMedix (NASDAQ:CRMD) and Amarin (NASDAQ:AMRN)

Amarin (NASDAQ:AMRN) and CorMedix (NASDAQ:CRMD) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Volatility & Risk

Amarin has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500.

Institutional and Insider Ownership

22.3% of Amarin shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 4.2% of Amarin shares are owned by insiders. Comparatively, 3.5% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Amarin and CorMedix”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65 million	1.16	-$38.80 million	($0.96)	-12.19
CorMedix	$311.71 million	1.33	$163.05 million	$2.14	2.48

CorMedix has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amarin and CorMedix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarin	-10.87%	-0.52%	-0.36%
CorMedix	40.49%	40.52%	20.61%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Amarin and CorMedix, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2	1	0	0	1.33
CorMedix	0	2	8	0	2.80

Amarin currently has a consensus target price of $13.00, suggesting a potential upside of 11.06%. CorMedix has a consensus target price of $15.44, suggesting a potential upside of 191.13%. Given CorMedix’s stronger consensus rating and higher possible upside, analysts clearly believe CorMedix is more favorable than Amarin.

Summary

CorMedix beats Amarin on 13 of the 14 factors compared between the two stocks.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on developing and commercializing therapies intended to reduce cardiovascular risk. Its principal product is VASCEPA (icosapent ethyl), a prescription omega-3 fatty-acid medicine derived from highly purified eicosapentaenoic acid. VASCEPA was initially approved in the United States to help lower triglyceride levels in certain patients and later received expanded approval to reduce the risk of cardiovascular events in eligible adults with elevated cardiovascular risk.

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.